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Background: The challenge of early tuberculosis (TB) infection
among rural patients accessing highly active antiretroviral therapy
(HAART) in a resource-limited setting with high HIV and TB
burden has not been fully quantified.
Methods: This is a retrospective study nested within a prospective
study of 969 patients consecutively initiated onto HAART at the
CAPRISA AIDS Treatment programme in rural KwaZulu-Natal
between January 2007 and December 2010. Patients were screened
for clinical symptoms consistent with TB using a standardized
checklist, and routine clinical investigations that included sputum
microscopy and chest x-ray diagnosis.
Results: Of 969 HIV-infected patients initiated on HAART, 173
[17.9%; 95% confidence interval (CI): 15.5 to 20.4] had active TB at
HAART initiation. TB incidence rates were 3-fold higher in the first 3
months (early incident TB) after HAART initiation [11.5/100 person-
years (py); 95% CI: 7.1 to 17.5] compared with 4–24 months (late
incident TB) post-HAART initiation (3.2/100 py; 95% CI: 2.2 to 4.5;
incidence rate ratio: 3.6; 95% CI: 2.0 to 6.4; P, 0.001). Immune status
of patients at HAART initiation did not impact TB incidence rates in
patients with CD4+ counts of ,50 (5.3/100) and .200 (4.9/100 py;
P = 0.81) cells per cubic millimeter. CD4+ count gains achieved 12
months post-HAART initiation were significantly different in patients
with early incident TB versus late incident TB; P = 0.03.
Conclusions: Rural HIV treatment programmes in TB-endemic
settings experience high rates of TB irrespective of immunologic
status of patients at HAART initiation, or duration on HAART.
Key Words: HIV, TB, tuberculosis, HAART, Africa, KwaZulu-
Natal, South Africa
(J Acquir Immune Defic Syndr 2014;65:438–446)
INTRODUCTION
Tuberculosis (TB) infection contributes substantially to
morbidity and mortality among HIV-positive patients. Glob-
ally, HIV-associated TB peaked in 2005 at 1.39 million cases
with approximately 15% incident cases and 480,000 deaths.1
However, 2010 data indicated a continuing burden of HIV-
associated TB with 1.1 million cases of TB of which 13%
were incident cases and resulting in approximately 350,000
deaths.2 KwaZulu-Natal, South Africa, is home to approxi-
mately 1.2 million HIV-infected individuals with 70% of TB
patients coinfected with HIV,3 and a TB notification rate of
1094 cases per 100,000 population.4,5
The use of highly active antiretroviral therapy
(HAART) in HIV-infected patients reduces the risk of
developing TB by 70%–90%6–9 and is therefore a key strat-
egy recommended by the World Health Organization (WHO)
to prevent TB.10 Studies from resource-limited settings show
that HIV-infected patients have higher rates of TB compared
with HIV-uninfected patients, and with longer duration on
HAART there is a decline in TB incidence rates.11,12
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Notwithstanding the evidence for TB screening and diagno-
sis, and HAART initiation early during TB therapy,13–16 the
burden of undiagnosed TB at HAART initiation and the num-
ber of new TB cases diagnosed during HAART in high HIV
and TB settings have not been fully measured. In rural dis-
tricts of KwaZulu-Natal where the TB and HIV epidemics
converge most dramatically, the TB burden and its impact
on patients at HAART initiation and during treatment remain
poorly documented.
The aim of this study was to measure the prevalence
and incidence rates of TB among patients accessing HAART
in a rural community-based programme in a high TB and HIV
prevalence setting in KwaZulu-Natal, South Africa, and
explores its impact on therapeutic outcomes.
METHODS
Study Population
We conducted a prospective cohort study among 969
HIV-positive patients initiated onto HAART at the Vulindlela
CAPRISA AIDS Treatment programme between January 01,
2007 and December 31, 2010. This rural community out-
patient clinic adjoins and receives patients from one of 7
primary health care clinics in an area serving a community of
about 400,000 people. Eligibility criteria were in accordance
with South African Government HIV/AIDS treatment guide-
lines at the time.17,18 Patients were screened for clinical symp-
toms consistent with TB using a standardized checklist that
asked about drenching night sweats, prolonged cough, fever,
and weight loss by either clinicians or professional nurses at
every clinical visit. Patients who screened positive were
referred to the adjacent government Primary Health Care
Clinic for TB smear testing. Smear-positive patients were
initiated onto anti-TB therapy while sputum culture testing
and antibiotic therapy was offered to all smear-negative pa-
tients. Smear- and culture-negative patients with poor
response to antibiotics, and those with suspected extrapulmo-
nary TB were referred to the local district hospital for chest x-
ray, abdominal ultrasonography, or other invasive investiga-
tions such as lymph node aspirate, tissue biopsy, and others.
Access to TB microbiology services was variable and de-
pended on the availability of skilled laboratory staff espe-
cially for culture and drug susceptibility testing and timeous
communication of results to site staff and patients. Tuberculin
skin testing and isoniazid preventive therapy (IPT) was not
the currently available standard of care during the study
period. Patients were seen monthly for the first 6 months
and every 3 months thereafter unless clinically indicated.
Routine demographic, laboratory, and clinical data were re-
corded at baseline and at follow-up visits. On TB diagnosis,
the following additional information was collected: date and
method of diagnosis, TB type [extrapulmonary TB (EPTB) or
pulmonary TB (PTB)], TB drug susceptibility pattern, and
date of TB treatment initiation and completion. Patients
who had both PTB and EPTB were then classified as having
EPTB. TB was diagnosed and treated as per South African
National TB Control Program guidelines.19 All patients
with complications or requiring further investigation and
management were referred to the closest district level services
about 30 km away.
For the purposes of this study, a patient with a “history of
TB” was defined as having completed TB treatment before
HAART initiation. Patients with a TB history were classified
as having a “recent history of TB” if they had an episode of TB
within the year before HAART initiation.20 A “prevalent case
of TB” was defined as a patient who was already on TB
treatment when HAART was initiated. “Incident TB cases”
were defined as new TB cases diagnosed after HAART initi-
ation and was further classified into “early incident TB”
defined as a new TB diagnosis within 3 months of HAART
initiation, and “late incident TB” defined as a new TB diagno-
sis occurring between 4 and 24 months post-HAART initia-
tion.20 A recurrent episode of TB after TB treatment
completion or cure for the TB episode present at baseline
was regarded as an incident TB case in the prevalent TB group.
Statistical Analysis
All reported P values are 2-sided. TB incidence was
calculated as number of new TB cases after HAART initiation
per 100 person-years (py) of follow-up. Data are presented as
proportions, means, or medians where appropriate. Study
duration for patients with no prevalent TB was calculated
from HAART initiation date to date of TB diagnosis, or pro-
gramme exit through loss to follow-up, transfer out, or death.
Patients with prevalent TB were included in the incidence
calculation and their time on study calculated from the date
treatment for prevalent TB was discontinued to either the date
of a new TB diagnosis, or to programme exit through loss to
follow-up, transfer out, or death. All patient data were cen-
sored at 24 months of follow-up.
Poisson approximations were used to calculate confi-
dence intervals (CIs) for TB incidence. Kaplan–Meier was
used to construct survival curves. Incidence rate ratios (IRRs)
were used to identify factors associated with early and late
incident TB. The following baseline covariates were used to
assess factors associated with early and late incident TB: age,
gender, weight, WHO stage HIV disease, number of previous
TB episodes, CD4+ counts, and viral load. Data were ex-
tracted from routinely collected data recorded on standardized
case report forms captured on a customized database through
datafax. Statistical analysis was performed using SAS (ver-
sion 9.2; SAS Institute Inc., Cary, NC).
This study was approved by the Biomedical Research




The study comprised 969 HIV-infected patients con-
secutively initiated on HAART between January 2007 and
December 2010. The demographic and clinical characteristics
at baseline are presented in Table 1. Approximately two-
thirds of the cohort was women (67.8%). The mean age
of patients was 34.3 years (SD 6 9.6 years). The median
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follow-up time was 11 [interquartile range (IQR), 6.7–19.6]
months, with 77.3% (749/969) of patients still in active
follow-up at 24 months post-HAART initiation. The median
baseline CD4+ count among patients with early incident TB,
late incident TB, with no TB, and in the entire cohort were
101 (IQR, 71–139), 112 (IQR, 34–204), 131 (IQR, 63–187),
and 128 (IQR, 61–186) cells per cubic millimeter, respec-
tively. The median baseline CD4+ count overall, among
patients with early incident TB, late incident TB, and with
no TB was 128 (IQR, 61–186), 101 (IQR, 71–139), 112
(IQR, 34–204), and 131 (IQR, 63–187) cells per cubic
millimeter, respectively. Approximately 50% of the cohort
presented with clinically evident WHO stage 3 HIV disease.
TB Status at HAART Initiation
At baseline, all 969 patients were offered a TB
symptom-screening checklist. The diagnosis of active TB
(prevalent TB group) was made in 173/969 patients (17.9%;
95% CI: 15.5 to 20.4). Two-thirds of patients with baseline
prevalent TB (68.6%) had PTB, 24.9% had EPTB, 4.0% had
both PTB and EPTB, and 2.3% had TB with the site
unspecified. Diagnosis of prevalent PTB (n = 119) was made
through sputum smear (n = 54/119), chest x-ray (n = 54/65),
clinical grounds only (n = 9/11), and missing data on method
of diagnosis (n = 2). The diagnosis of prevalent EPTB (n =
43) was made through diagnostic radiology (n = 25), lymph
node aspirate (n = 4), joint aspirate (n = 1), histology from
biopsy specimen (n = 2), on clinical grounds (n = 5), and
unknown (n = 6). Seven patients had both PTB and EPTB at
baseline, diagnosed on sputum smear (n = 1/7), chest x-ray
(n = 2/7), clinical grounds only (n = 2/7), diagnostic radiology
(n = 1/7), and pleural tap (n = 1/7). There were 226 patients
with a history of TB (80 in the prevalent TB group and 146 in
the group without prevalent TB at baseline) of which 61.5%
had an episode of TB within the year before HAART initia-
tion (recent history) (Fig. 1). TB prevalence stratified by
immune status is presented in Table 2. Prevalent TB was
highest among patients with CD4+ counts of ,50 cells per
cubic millimeter (25.1%, 47/187; 95% CI: 19.2 to 32.1).
Incident TB Infections
There were 54 new clinical TB cases identified after
HAART initiation giving an overall TB incidence rate of 4.5
per 100 py (95% CI: 3.3 to 5.8). There were 3 cases of
incident TB in the group with prevalent TB at the time
of HAART initiation. Early incident TB was 3-fold higher
(11.5/100 py; 95% CI: 7.1 to 17.5) compared with late
incident TB (3.2/100 py, 95% CI: 2.2 to 4.5; IRR, 3.6; 95%
CI: 2.0 to 6.4; P, 0.001) (Fig. 2). Diagnosis of incident PTB
(N = 29) was made through sputum smear (n = 7/29), chest
x-ray (n = 19/29), sputum culture (n = 1/3), and clinical
grounds only (n = 2/29). Diagnosis of incident EPTB (n =
23) was made through diagnostic radiology (n = 13/19), pleu-
ral tap (n = 1/1), histology from biopsy specimen (n = 1/1),
clinical grounds only (n = 5/23), and unknown (n = 3). Two
patients with incident TB had both PTB and EPTB, which
was diagnosed by diagnostic radiology.
Risk Factors for Early and Late Incident TB
The rate of early incident TB was almost 2-fold higher
among female; 13.3/100 py; (95% CI: 7.6 to 21.3) compared
with male patients; 7.3/100 py; (95% CI: 2.0 to 18.8; IRR,
1.8; 95% CI: 0.6 to 7.4; P = 0.21), and almost 5-fold higher
among patients aged between 24 and 34 years (17.8/100 py,
95% CI: 10.0 to 29.4) compared with $35 years (3.8/100 py,
95% CI: 0.8 to 11.1; IRR, 4.7; 95% CI: 1.3 to 25.2; P = 0.01)
(Table 3). However, interaction between gender and age was












Age (yrs), mean 6 SD† 34.3 6 9.6 34.5 6 9.8 33.9 6 8.3 29.3 6 5.3 35.5 6 11.3
No. females, n (%)‡ 651 (67.8) 509 (69.2) 103 (59.5) 17 (81.0) 24 (72.7)
Weight (kg), mean 6 SD§ 61.0 6 13.5 62.0 6 14.1 56.9 6 10.6 62.4 6 12.6 58.1 6 11.4
BMI (kg/m2) ,18.5, n (%)k 119 (13.4) 75 (10.9) 37 (23.3) 2 (10.5) 5 (17.2)
Viral load (log copies/mL), mean 6 SD¶ 4.9 6 0.9 4.9 6 0.9 5.3 6 0.9 5.2 6 1.1 5.1 6 0.7
CD4+ cell count (cells/mm3), median (IQR)# 128 (61–186) 139 (71–190) 97 (41–147) 104 (71–139) 112 (34–204)
WHO Stage 3 of HIV Disease, n (%)** 567 (59.3) 365 (49.8) 166 (96.0) 16 (76.2) 23 (71.9)
History of TB at HAART initiation, N = 947 (%) 226 (23.9) 133 (18.3) 80 (46.8) 5 (23.8) 9 (28.1)
Recent TB history, n (%) 139 (61.5) 62 (46.6) 74 (92.5) 1 (20.0) 3 (33.3)
Remote past TB history, n (%) 87 (38.5) 71 (53.4) 6 (7.5) 4 (80.0) 6 (66.7)
BMI, body mass index.
*Three patients who developed late incident TB had prevalent TB.
†Ten patients had missing age.
‡Nine patients have missing gender.
§Eleven patients had missing weight.
kSeventy-eight patients had missing BMI data.
¶One hundred seventy-two patients had missing viral load.
#Eighty-six patients had missing CD4+ count data.
**Thirteen patients have missing WHO data.
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not statistically significant (P = 0.10). No other factors were
found to be associated with incident TB.
Baseline immune status of patients did not impact
overall TB incidence rates; patients with CD4+ counts of ,50
cells per cubic millimeter had TB incidence rates of 5.3/100
py (95% CI: 2.7 to 9.3) compared with 4.9/100 py (95% CI:
2.4 to 9.0) in patients with CD4+ counts of .200 cells per
cubic millimeter (P = 0.81). Additionally, baseline immune
status did not impact rates of incident TB.
TB incidence rates 3 months post-HAART initiation
among patients with CD4+ counts of ,50, between 50 and
200, and .200 cells per cubic millimeter were 4.6 (95% CI:
2.1 to 8.8), 2.4 (95% CI: 1.3 to 4.0), and 4.7 (95% CI: 2.0 to
9.2) per 100 py (Table 2).
Impact on Therapeutic Outcomes
There were 51 incident cases of TB among patients
with no prevalent TB at baseline (26 PTB, 25 EPTB), and 3
incident cases of PTB among patients with prevalent TB at
baseline. There was one case of multidrug-resistant TB in this
cohort. Patients with incident PTB and EPTB had similar
median baseline CD4+ counts, 106 versus 129 cells per cubic
millimeter (P = 0.57), and baseline log viral loads, 5.2 versus
FIGURE 1. Flowchart depicting TB
burden in a community-based
HAART programme. History of TB
information was available for 947
individuals. Cohort included all pa-
tients enrolled onto HAART between
January 2007 and December 2010,
with patient follow-up time from
enrollment date up until June 2011,
when database was closed. History
of TB: patient who completed TB
treatment before HAART initiation;
recent history of TB: episode of TB
within the year before HAART initia-
tion; remote history of TB: TB epi-
sode more than a year before HAART
initiation; prevalent TB: patient for
whom treatment was ongoing dur-
ing HAART initiation; incident TB:
new cases of TB diagnosed after
HAART initiation, which was further
divided into early incident TB
defined as a new TB diagnosis within
3 months of HAART initiation, and
late incident TB defined as new TB
diagnosis 4–24 months post-HAART initiation. PTB, pulmonary TB; EPTB, extrapulmonary TB, including cases of both PTB and
EPTB; CAT, The Centre for the AIDS Programme of Research in South Africa (CAPRISA) AIDS Treatment Programme.







(N = 745) Prevalent TB (N = 173) Early Incident TB (N = 21)* Late Incident TB (N = 33)†





















Missing 86 (8.9) 63 (8.5) 17/86 19.8 (12.3 to 30.0) 4/14.9 26.9 (7.3 to 68.8) 2/75.6 2.6 (0.3 to 9.6)
CD4+ count
,50/mm3
187 (19.3) 129 (17.3) 47/187 25.1 (19.2 to 32.1) 3/31.1 9.6 (2.0 to 28.2) 9/195.1 4.6 (2.1 to 8.8)
CD4+ count
50–200/mm3
535 (55.2) 423 (56.8) 87/535 16.3 (13.3 to 19.7) 12/104.2 11.5 (5.9 to 20.1) 14/586.4 2.4 (1.3 to 4.0)
CD4+ count
.200/mm3
161 (16.6) 130 (17.4) 22/161 13.7 (9.0 to 20.2) 2/33.1 6.0 (0.7 to 21.8) 8/170.8 4.7 (2.0 to 9.2)
n, number of patients.
*New TB diagnosis in the first 3 months after HAART initiation.
†TB incidence between 4 and 24 months post-HAART initiation.
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5.0 (P = 0.19); and similar mean CD4+ count increases (P =
0.17) and log viral load decreases (P = 0.16) from baseline to
12 months post-HAART initiation. The median (IQR) months
on HAART to a new episode of TB was 3.7 (0.8–10.9) and
5.2 (1.6–10.8) in the PTB and EPTB groups, respectively.
Median CD4+ count change from baseline to 12 months
post-HAART initiation was significantly higher in patients
experiencing early incident 167 (IQR, 141–235) versus late
incident 76 (IQR, 32–187) cellsper cubic millimeter TB
(P = 0.03) (see Table S1, Supplemental Digital Content,
http://links.lww.com/QAI/A486).
Mortality Rates
There were 57 deaths in this cohort with an overall
mortality rate of 4.3 per 100 py (95% CI: 3.3 to 5.6). There
were 7 deaths among patients with baseline prevalent TB,
mortality rate of 2.7 (95% CI: 1.1 to 5.6) per 100 py
compared with 50 deaths among 796 patients with no baseline
prevalent TB, mortality rate of 4.7 (95% CI: 3.5 to 6.3) per
100 py (P = 0.20) of follow-up. Patients with at least 1 epi-
sode of TB (either history, prevalent or incident TB) had
a lower mortality rate 3.4 (95% CI: 2.0 to 5.4) compared with
patients with no TB, 4.5 (95% CI: 3.1 to 6.3) per 100 py
(IRR, 0.8; 95% CI: 0.5 to 1.4; P = 0.42) of follow-up. There
was 1 death each in the early and late incident TB groups. The
causes of death for 29 of 57 patients was known, and this
included PTB (n = 4), EPTB (n = 5), complications from
severe gastroenteritis (n = 6), trauma (n = 2), natural causes
(n = 5), meningitis-unknown cause (n = 2), lower respiratory
tract infection (n = 2), cerebrovascular accident (n = 1), intra-
cranial lesion (n = 1), and complications from hyperlactatemia
(n = 1). Causes of death were not available in 28 patients as
many of them died at home.
DISCUSSION
In a rural HIV treatment programme in a TB endemic
setting, we found unacceptably high TB incidence rates
irrespective of baseline immunologic status of patients at
HAART initiation, or duration on HAART. We document
TB incidence rates of 4.5/100 py of follow-up among HIV-
infected patients receiving community-based HAART care
in a rural setting. This incidence is higher than reports
from other sub-Saharan countries and most other high TB
burden settings2,21,22 and nearly 10-fold higher than re-
ported among HIV-negative patients from a setting with
similar TB notification rates.23 Thus, we provide further
evidence for continued susceptibility of HAART-
accessing patients to TB infection in a hyper-endemic
TB setting sustained over 2 years post-HAART initiation.
This continued susceptibility to TB despite HAART likely
points to ongoing community-level and possibly nosoco-
mial TB transmission.
We demonstrate an alarmingly high and consistent
TB incidence (Table 2) among all baseline CD4+ count
strata during study follow-up. The data show an inverse
relationship between time on HAART and TB incidence,
corroborating past studies, and likely because of greater
TB-specific immune restoration with time spent on
HAART.6,24–26 Furthermore, we highlight the need for
close clinical observation in the first few months post-
HAART initiation by demonstrating highest rates of inci-
dent TB, likely because of “unmasked” infection, in the
FIGURE 2. Kaplan–Meier estimates of cumulative
probability of developing early incident TB.
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first 3 months post-HAART initiation. Additionally, the contin-
ued high rate of new TB infections even at 24 months post-
HAART initiation is in keeping with published reports showing
that, despite its decline with time on HAART, TB incidence
among a HAART-accessing HIV population remains higher
than in the general HIV-uninfected population.27 We speculate
that the high TB incidence rates observed in this study may be
because of either impaired restoration of TB specific immunity
when patients are severely immune compromised (baseline
CD4+ counts#200 cells/mm3) at HAART initiation, or because
of high ongoing community level TB transmission. The inci-
dence rates observed are most likely because of a combination
of both these factors. Interestingly, although women carry a dis-
proportionate burden of HIV in sub-Saharan Africa, and despite
finding a 2-fold higher rate of early incident TB in women
compared with men, further analysis stratified by age and gender
showed no statistically significant difference in risk for either
early or late incident TB. Notwithstanding lower pre-HAART
CD4+ counts among patients who developed early incident TB,
therapeutic outcomes among patients at 12 months post-
HAART initiation was similar in all groups.
In contrast to our study, published literature demon-
strates a far more substantial time-dependant reduction in TB
incidence among patients on HAART.28–37 These studies
report highest TB incidence during the first 3 months of
HAART10 with a progressive reduction of all forms of TB
during the first year of follow-up from 5.77/100 to 2.23/100
py.38 Published meta-analysis data from developed country
cohorts estimate a comparable effect of HAART on TB inci-
dence despite differences in background risk of
TABLE 3. Predictors of Early and Late Incident TB
Risk Factor










Missing 0/1.3 — 0/2.8
,24 3/19.2 15.6 (3.2 to 45.6) 4.1 (0.5–30.5) 4/97.0 4.1 (1.1 to 10.6) 1.1 (0.2–3.8)
24–34 15/84.2 17.8 (10.0 to 29.4) 4.7 (1.3–25.2) 14/492.8 2.8 (1.6 to 4.8) 0.8 (0.4–1.8)
35+ 3/78.7 3.8 (0.8 to 11.1) Reference 15/435.2 3.4 (1.9 to 5.7) Reference
Gender
Missing 0/1.2 — 0/2.8
Male 4/54.5 7.3 (2.0 to 18.8) Reference 9/326 2.8 (1.3 to 5.2) Reference
Female 17/127.6 13.3 (7.6 to 21.3) 1.8 (0.6–7.4) 24/699 3.4 (2.2 to 5.1) 1.2 (0.6–3.0)
BMI (kg/m2)
Missing 2/11.9 16.8 (2.0 to 60.7) 4/64.6 6.2 (1.7 to 15.8)
,18.5 2/18.2 11.0 (1.3 to 39.7) 0.9 (0.1–4.3) 5/119.7 4.2 (1.4 to 9.7) 1.6 (0.4–5.7)
18.5–25 9/90.7 9.9 (4.5 to 18.8) 0.8 (0.3–2.3) 16/527.4 3.0 (1.7 to 4.9) 1.2 (0.5–3.2)
.25 8/62.5 12.8 (5.5 to 25.2) Reference 8/316.1 2.5 (1.1 to 5.0) Reference
WHO clinical stage of HIV
disease
Missing 0/1.8 — 1/5.6 17.8 (0.5 to 99.2)
3 or 4 16/89.4 17.9 (10.2 to 29.1) Reference 23/587.6 3.9 (2.5 to 5.8) Reference
1 or 2 5/92.2 5.4 (1.8 to 12.7) 0.3 (0.1–0.9) 9/434.6 2.1 (0.9 to 3.9) 0.5 (0.2–1.2)
No. previous episodes of TB
Missing 0/3.3 1/14.4 7.0 (0.2 to 38.7)
0 16/146.2 10.9 (6.3 to 17.8) Reference 21/653.9 3.2 (2.0 to 4.9) Reference
1 5/33.9 14.8 (4.8 to 34.4) 1.3 (0.4–3.9) 10/257.1 3.9 (1.9 to 7.2) 1.2 (0.5–2.7)
2 — — 1/102.4 1.0 (0 to 5.4) 0.3 (0–1.9)
CD4+ count (cells/mL3) at
HAART initiation
Missing 4/14.9 26.9 (7.3 to 68.8) 2/75.6 2.6 (0.3 to 9.6) —
,50 3/31.1 9.6 (2.0 to 28.2) 1.6 (0.2–19.1) 9/195.1 4.6 (2.1 to 8.8) 1.0 (0.3–2.9)
50–200 12/104.2 11.5 (5.9 to 20.1) 1.9 (0.4–17.6) 14/586.4 2.4 (1.3 to 4.0) 0.5 (0.2–1.4)
.200 2/33.1 6.0 (0.7 to 21.8) Reference 8/170.8 4.7 (2.0 to 9.2) Reference
Viral load at HAART initiation
(log copies/mL)
Missing 6/31.2 19.2 (7.1 to 41.8) 8/210.4 3.8 (1.6 to 7.4) —
,5 4/80.7 5.0 (1.4 to 12.7) 0.3 (0.1–1.1) 13/387.8 3.4 (1.8 to 5.7) 1.2 (0.5–2.9)
$5 11/71.5 15.4 (7.7 to 27.5) Reference 12/429.6 2.8 (1.4 to 4.9) Reference
*Early incident TB is defined as a new TB diagnosis within 3 months of HAART initiation.
†Late incident TB defined as new TB diagnosis 4–24 months post HAART initiation.
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Mycobacterium tuberculosis infection. These data provide an
estimated TB incidence of 3 cases per 1000 py among pa-
tients accessing HAART, 10-fold lower compared with the
TB incidence rates we found.10 Findings similar to ours were
reported in only 1 other study, conducted in a densely popu-
lated urban informal settlement with an HIV seroprevalence
of 28% and TB notification rate of .1000/100,000 popula-
tion. In this study, TB incidence was reduced from 22.1 to
4.5/100 py among patients with a median baseline CD4+
count of 96 cells per cubic millimeter (IQR, 46–156), after
approximately 3 years of HAART.39
The vast majority of TB episodes among patients with
a previous TB history occurred in the 5-year period immedi-
ately before HAART initiation, a likely clinical feature of
symptomatic HIV disease. We demonstrated a TB prevalence
rate of 17.9% among HIV-infected patients initiating HAART,
lower than previous reports from a South African community-
based HAART program.39 Other published studies from
resource-limited settings report a high TB prevalence at
HAART enrollment25,39 primarily among patients with CD4+
count ,50 cells per cubic millimeter. However, data from this
study show high rates of prevalent TB especially in lower
baseline CD4+ count strata and not only among those severely
immune compromised.40 Among patients enrolling on
HAART, 1 in 4 with CD4+ counts of ,100 cells per cubic
millimeter and 1 in 7 patients with CD4+ counts of $100 cells
per cubic millimeter had active TB. It is important to note,
however, that excluding active TB among HIV-infected pa-
tients is usually complex owing to high rates of smear-
negative TB and difficulty of diagnosing asymptomatic or sub-
clinical TB, common among patients accessing HAART.41,42
Unsurprisingly, there was no statistically significant
difference in mortality rates among cases with known TB at
baseline compared with those without. Mortality studies
among HIV-infected patients conducted in this setting have
repeatedly demonstrated high rates of undiagnosed TB
responsible for as much as 79% of all deaths in HIV-
infected patients.43,44 Mortality rates were similar among pa-
tients with new episodes of EPTB as compared with those
with new episodes of PTB; 2.3 (95% CI: 0.1 to 13.1) versus
2.1 (95% CI: 0 to 11.6) per 100 py of follow-up. Interestingly,
the mortality rate at 24 months in this study among patients
with and without prevalent TB at baseline was very different
to 5-year mortality rates of 4.84 and 2.62 per 100 py of
follow-up among prevalent TB and TB-free patients initiating
antiretroviral therapy in Cape Town, South Africa.45
Although it may be likely that most cases of early
incident TB was due to immune reconstitution inflammatory
syndrome (IRIS), it remains unclear as to what proportion of
incident TB was due to “unmasking” versus “paradoxical” TB
IRIS versus new TB infections. It is well understood that IRIS
embodies an interpretive crisis because its clinical diagnosis is
similar to TB treatment failure, drug toxicities, TB relapse, or
new AIDS-defining illness,46 and cannot be diagnosed by avail-
able tests.47 Although consensus case definitions for TB IRIS
have been formulated,20 the translation of these guidelines to the
bedside remains poor. It is likely that this study underestimated
rates of TB IRIS due to the poor ability to diagnose this phe-
nomenon. In addition, in the absence of chest x-rays, minimally
symptomatic or asymptomatic pulmonary disease may be incor-
rectly attributed to HIV or to other opportunistic infections.
We acknowledge several limitations. This study was
conducted in a hyper-endemic HIV and TB setting, which
limits the generalizability of these findings to similar settings.
Limited access to chest x-rays in this primary health care
setting, especially for asymptomatic patients with low CD4+
counts may have led to significant underreporting of TB, which
potentially limits the validity, and to a lesser extent the gener-
alizability of the study. The reliance on TB clinical symptom
screening, lack of use of a standardized algorithm for TB
screening and diagnosis, together with limited access to TB
microscopy services, further contributed to TB cases being
missed. The findings from this study highlight the need for
enhanced screening and the use of a diagnostic algorithm for
TB in a setting with generalized TB and HIV co-epidemics.
High rates of smear-negative TB and long delays in TB diag-
nosis may have led to the misclassification of prevalent TB
cases as incident TB, especially for episodes that occurred in
the first 3 months post-HAART initiation. Data used were rou-
tinely collected programmatic data, and missing data elements
may have led to an underestimation of the actual burden of TB
in this setting. Additionally, TB outcome data were not always
readily available for complicated patients referred for hospital-
ization or for those who were lost to follow-up. In contrast to
published literature, we report low IRIS estimates, which may
be because of the retrospective nature of this study and to the
lack of standardized clinical tools for diagnosing IRIS. Molec-
ular strain typing would have been extremely useful in deter-
mining if cases of recurrent TB in this cohort were due to
relapse or reinfection, particularly in patients with early incident
TB and in the 3 cases with incident and recurrent TB, but given
the lack of cost-effective but unavailable tools such as chest x-
rays in this setting, such endeavors were unfortunately unreal-
istic. It is important to note that our health care facility imple-
mented standard WHO TB infection control measures, and data
for this study were collected before the programmatic imple-
mentation of IPT. The impact of IPT on TB prevalence and
incidence in community-based HAART programmes remains
to be explored, however, in this cohort it is important to note
that starting patients on IPT with HAART may result in many
patients with active TB disease having initiated IPT.
CONCLUSIONS
Our study on the prevalence and incidence of TB in
a rural, community-based HIV treatment programme has
described a disproportionately high TB burden in patients
accessing HAART. Our findings highlight the urgent need to
implement TB-preventive therapy and TB infection control
practices in HAART programmes in endemic settings. TB
incidence by baseline CD4+ count is highest among patients
with CD4+ count of ,50 cells per cubic millimeter40; how-
ever, we also observed high TB incidence rates at higher
CD4+ counts. Therefore, despite apparent immunologic
recovery among HAART-accessing HIV patients, high TB
incidence is still a potent threat, possibly reflecting commu-
nity and nosocomial TB transmission. The availability of
point-of-care diagnostic assays such as GeneXpert that
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readily diagnose TB while patients queue for services will
facilitate TB case finding before the start of HAART, thereby
reducing TB-related morbidity and mortality commonly
found among patients newly enrolled into HAART pro-
grammes in TB-endemic setting.
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